MAGE genes: Prognostic indicators in AL amyloidosis patients
MAGE genes: Prognostic indicators in AL amyloidosis patients
复制标题
MAGE 基因：AL 淀粉样变性患者的预后指标
DOI：
10.1111/jcmm.14475
复制
发表时间：
2019-08-01
影响因子：
5.3
通讯作者：
Lu，Jin
中科院分区：
文献类型：
--
作者：
Liu，Yang;Wen，Lei;Lu，Jin
MAGE-CT(癌睾丸)抗原在多发性骨髓瘤(MM)患者中表达频率很高，但在其他浆细胞癌中，其潜在功能尚不清楚。我们采用实时定量聚合酶链式反应检测了2013年6月至2018年1月北京大学人民医院105例新诊断的淀粉样轻链淀粉样变性患者MAGE-CT基因(MAGE-C1/CT7、MAGE-A3、MAGE-C2/CT10)的表达。初诊AL患者中MAGE-C1/CT7、MAGE-C2/CT10和MAGE-A3的阳性表达率分别为83.8%(88/105)、56.71%(38/67)和22.0%(13/59)。器官倾向性与MAGE-CT基因表达无明显相关性。MAGE-C1/CT7水平的变化与治疗效果一致。MAGE-C1/CT7、MAGE-C2/CT10和MAGE-A3的表达水平为AL淀粉样变性患者的辅助诊断和疗效监测提供了潜在的有效临床指标。
A high frequency of MAGE‐CT (cancer testis) antigens are expressed in Multiple Myeloma (MM) patients; however, in other plasma cell dyscrasias, their potential function remains unclear. We measured the expression of MAGE‐CT genes (MAGE‐C1/CT7, MAGE‐A3, MAGE‐C2/CT10) in 105 newly diagnosed amyloid light‐chain (AL) amyloidosis patients between June 2013 and January 2018 at Peking University People's Hospital using real‐time quantitative polymerase chain reaction. In the newly diagnosed AL patients, the positive expression rates of patients with MAGE‐C1/CT7, MAGE‐C2/CT10 and MAGE‐A3 were 83.8% (88/105), 56.71% (38/67) and 22.0% (13/59) respectively. There was no significant correlation between organ propensity and MAGE‐CT gene expression. Changes in the MAGE‐C1/CT7 levels were consistent with a therapeutic effect. The expression levels of MAGE‐C1/CT7, MAGE‐C2/CT10 and MAGE‐A3 provide potentially effective clinical indicators for auxiliary diagnoses and monitoring treatment efficacy in AL amyloidosis patients.